Cancer‐testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis

Lina Lin; Weixia Nong; Bin Luo; Yingying Ge; Xia Zeng; Feng Li; Rong Fan; Qingmei Zhang; Xiaoxun Xie

doi:10.1002/iid3.534

Immunity, Inflammation and Disease (Dec 2021)

Cancer‐testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis

Lina Lin,
Weixia Nong,
Bin Luo,
Yingying Ge,
Xia Zeng,
Feng Li,
Rong Fan,
Qingmei Zhang,
Xiaoxun Xie

Affiliations

Lina Lin: Department of Histology and Embryology, School of Preclinical Medicine Guangxi Medical University Nanning China
Weixia Nong: Department of Histology and Embryology, School of Preclinical Medicine Guangxi Medical University Nanning China
Bin Luo: Department of Histology and Embryology, School of Preclinical Medicine Guangxi Medical University Nanning China
Yingying Ge: Department of Histology and Embryology, School of Preclinical Medicine Guangxi Medical University Nanning China
Xia Zeng: Department of Histology and Embryology, School of Preclinical Medicine Guangxi Medical University Nanning China
Feng Li: Department of Histology and Embryology, School of Preclinical Medicine Guangxi Medical University Nanning China
Rong Fan: Department of Histology and Embryology, School of Preclinical Medicine Guangxi Chinese Medicine University Nanning China
Qingmei Zhang: Department of Histology and Embryology, School of Preclinical Medicine Guangxi Medical University Nanning China
Xiaoxun Xie: Department of Histology and Embryology, School of Preclinical Medicine Guangxi Medical University Nanning China

DOI: https://doi.org/10.1002/iid3.534
Journal volume & issue: Vol. 9, no. 4
pp. 1759 – 1770

Abstract

Read online

Abstract Introduction Cancer testis (CT) antigens are attractive targets for cancer immunotherapy because of their expression restriction and immunogenicity. The acrosin binding protein (ACRBP) is a member of CT antigens. This study aimed to evaluate ACRBP expression and immunogenicity in ovarian cancer (OC). Methods The expression level of ACRBP in OC tissues, normal ovarian tissues, and cell lines was detected via quantitative real‐time polymerase chain reaction (qRT‐PCR) and immunohistochemistry. We determined the levels of ACRBP antigen and antibody in serum samples collected from patients with OC and healthy donors using enzyme‐linked immunosorbent assays (ELISA), the level of ACRBP in cell‐cultured medium was also tested. Results ACRBP mRNA and protein expressions were upregulated in OC tissues relative to normal tissue, especially highly expressed in epithelial ovarian cancer (EOC). Moreover, ACRBP expression was significantly correlated with International Federation of Gynecology and Obstetrics (FIGO) stage and chemosensitivity. Serological analysis showed that anti‐ACRBP antibody was detected in the sera of 16 of the 56 (28.5%) patients with OC but not in healthy donors. The area under the receiver operating characteristic curve for ACRBP antibody was 0.802 (95% confidence interval [CI]: 0.708–0.876), and the sensitivity and specificity for ACRBP antibody was 85.71% and 55.0%, respectively. Kaplan–Meier analysis revealed that the overall survival (OS) and disease‐free survival (DFS) in OC patients with high ACRBP expression were significantly lower than those with low expression (p = 0.040, p = 0.021). However, ACRBP antibody level was not associated with prognosis. Conclusion ACRBP expression was upregulated in OC tissues and induced humoral immune response in patients with OC, suggesting that ACRBP is a potential prognostic biomarker and a target of tumor immunotherapy for OC.

Published in Immunity, Inflammation and Disease

ISSN: 2050-4527 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: https://onlinelibrary.wiley.com/journal/20504527

About the journal

Abstract

Keywords